Federal standards, employer preparedness plans need improving to protect frontline workers: study … Joint federal agency letter urges utility data access for affordable housing providers … LeadingAge...
Legislation aims to ensure ‘fair and accurate’ Alzheimer’s treatment coverage decisions
By
Kimberly Bonvissuto
Nov 21, 2023
Federal legislation that would prevent the federal government from imposing wide-reaching coverage restrictions on Alzheimer’s treatments was reintroduced last week, providing “fair and accurate”...
Bipartisan group of 23 state AGs joins call for unrestricted coverage of Alzheimer’s treatments
By
Kimberly Bonvissuto
May 03, 2023
A bipartisan group of attorneys general from 23 states have joined a growing chorus calling on Medicare to reverse a previous decision and provide unrestricted coverage of Food and Drug Administration-approved...
Lawmakers turn up heat on CMS to expand access to Alzheimer’s treatments
By
Kimberly Bonvissuto
Apr 28, 2023
Medicare needs to reconsider its national coverage decision on FDA-approved Alzheimer’s drug treatments, bipartisan members of the House told Centers for Medicare & Medicaid Services Administrator Chiquita...
Lawmakers chide HHS for ‘eroding the pathway’ to Alzheimer’s treatments
By
Kimberly Bonvissuto
Mar 24, 2023
With personal stories of the effects that Alzheimer’s disease has had on them, lawmakers in a Senate Finance Committee hearing on Wednesday called for the federal government to speed up access to treatments....
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.
More news for Wednesday, May 4
By
Kimberly Bonvissuto
May 04, 2022
Occupancy trends up after omicron slump: Omega … AHCA / NCAL launches Diversity Executive Leadership Program … How to support older adults related to gun ownership decisions, suicide prevention …...
More news for Friday, April 8
By
Kimberly Bonvissuto
Apr 08, 2022
CBRE Seniors Housing & Care Investor Survey identifies industry trends … Senior housing staffing shortages move from severe to moderate: NIC … CMS finalizes Medicare coverage policy for Alzheimer’s...
Expert panel publishes first recommendations on appropriate use of Alzhemier’s drug Aduhelm
By
Kimberly Bonvissuto
Jul 27, 2021
A panel of experts in the Alzheimer’s field this morning published the first recommendations for the appropriate use of aducanumab (Aduhelm), the controversial new drug to treat early, mild disease.
